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To this day, empirical data suggests that zinc has important roles in matrix synthesis, 
bone turnover, and mineralization and its beneficial effects on bone could be 
mediated through different mechanisms. The influence of zinc on bone turnover 
could be facilitated via regulating RANKL/RANK/OPG pathway in bone tissue. 
Therefore, the aim of the study was to conduct a review to investigate the possible 





A comprehensive systematic search was performed in MEDLINE/PubMed, 
Cochrane Library, SCOPUS, and Google Scholar to explore the studies investigating 
the effect of zinc as a bone remodeling factor via RANKL/RANK/OPG pathway 
regulation. Subsequently, the details of the pathway and the impact of zinc 































































The pathway could play an important role in bone remodeling and any imbalance 
between RANKL/RANK/OPG components could lead to extreme bone resorption. 
Although the outcomes of some studies are equivocal, it is evident that zinc 
possesses protective properties against bone loss by regulating the 
RANKL/RANK/OPG pathway. There are several experiments where zinc 
supplementation resulted in upregulation of OPG expression or decreases RANKL 





It is likely that sufficient zinc intake will elicit positive effects on bone health by 
RANKL/RANK/OPG regulation. Although the outcomes of a few studies are 
equivocal, it seems that zinc can exert the protective properties against bone loss 
 
by suppressing osteoclastogenesis via downregulation of RANKL/RANK. 
Additionally, there are several experiments where zinc supplementation resulted in 
 
upregulation of OPG expression. However, the results of limited studies oppose this.
Therefore, aside from the positive role zinc possesses in preserving bone 
 













































































The skeleton is responsible for enduring mechanical load in the body and plays some 
important roles in inflammation, hormonal and mineral challenges in the body. 
Further, it is suggested that the skeleton may influence the parenchymal function of 
organs such as the kidney and pancreas by secreting some agents [1]. As a connective 
tissue, the skeleton has 4 types of cells including osteoblasts, osteoclasts, osteocytes, 
and bone lining cells. Bone tissue is perpetually in turnover; where osteoblasts 
control the formation of bone, and osteoclast activities lead to bones resorption. [2]. 
Bone mass is mainly comprised of minerals in varying types and combinations, such 
as hydroxyapatite, proteins including collagen and noncollagenous proteins, water 
and etc. each of these components is influencing by gender, disease, age, and site 
[3]. There are many risk factors that may deleteriously impact skeleton health, 
including low calcium level, vitamin D deficiency, sedentary lifestyle, hyperthyroid 
and hypothyroid, high blood pressure, high-stress level, hysterectomy, and 




























































mainly involve the skeleton include osteoporosis, rickets, osteomalacia, renal 
osteodystrophy, Paget's disease and malignancy of bone [5]. When bone mass 
reduced, some harmful change appear in bone structure [6]. Further, bone health is 
weakened as people age, especially in developing countries [7]. In Britain, 1 in 5 
men and 1 in 2 women over fifty years old, suffer from at least one fracture during 
their lifetime [8]. Based on recent findings, over 200 million people suffer from 
osteoporosis, globally [9], with most fractures occurring in the hips and forearm 
[10]. Although the actual effects of pharmacological agents on bone disorders is not 
yet clear; there is a burgeoning field of research dedicated to elucidating potential 
interactions. Some of the most common drugs in bone diseases include 
bisphosphonates, denosumab, estrogen, PTH peptide, Strontium ranelate, DKK1, 
and sclerostin antibodies, and calcium-sensing receptor antagonists [11]. On the 
other side, there are some medications that may have negative influences on bone 
health, including thyroid medications [12], anti-diabetic drugs [13], proton pump 
inhibitors [14], and antidepressants [15]. In order to preserve bone health, sufficient 
and persistent intake of some nutrients such as vitamin D, vitamin K, vitamin A, 
calcium, magnesium, fluoride, phosphorus, copper, potassium and zinc are 
necessary [16]. With a proper nutritional strategy, it is conceivable that reductions 
in bone loss, especially at early ages when the genome still has time for epigenetic 
































































Zinc is one of the important minerals for growth and bone health preservation; whilst 
deficiency in zinc has multiple complications, including diarrhea, alopecia immune 
dysfunction, growth retardation, and cognitive impairment. Aging, bone resorption 
and post-menopause all act to reduce zinc quantities in bone [17-19]. Zinc is required 
for protein and DNA synthesis in the skeleton [20, 21], whilst zinc deficiency leads 
to a major reduction in collagen synthesis and turnover [21]. It is also a stimulant for 
osteoblastic cells and suppresses osteoclast activity [22]. Empirical data suggests 
that zinc has important roles in matrix synthesis, mammalian system and probably 
in bone mineralization [23], and its protective and beneficial effects on bone could 
be mediated through cell proliferation, increasing collagen production, and 
stimulation alkaline phosphatase activity [24]. Furthermore, influence on bone 
turnover could be facilitated via zinc regulating RANKL/RANK/OPG pathway in 
bone tissue [25]. Zinc could inhibit the osteoclastogenesis which is induced by 
RANKL (receptor activator of NF-KB ligand) [19]. The pathway and its components 
are part of the tumor necrosis factor (TNF) superfamily, which could play an 
important role in bone remodeling. RANKL/RANK axis control osteoclasts 
formation and activity [26]. Moreover, these are identifying as key indicators on 
bone turnover in bone-related pathological situations. OPG, as the RANKL`s decoy 




























































protective role by binding to RANKL and prevention of bone resorption [26]. The 
imbalance between RANKL and OPG could lead to extreme bone resorption [26]. 
 
Although, there are several studies depicting the beneficial effects of zinc on bone 
health; the current evidence is not enough to approve the bone protective role of 
 
zinc supplementation in respect to RANKL/RANK/OPG balance. Therefore, the 
aim of this study was to review the effect of zinc supplements on regulation of 
RANKL/RANK/OPG axis which will help the future studies to focus and assist in 
developing potent strategies for treating patients with bone disorders. 
 
A comprehensive systematic search was performed in MEDLINE/PubMed, 
Cochrane Library, SCOPUS, and Google Scholar to explore the studies 
investigating the effect of zinc as a bone remodeling factor via 
RANKL/RANK/OPG pathway regulation. We comprehensively searched through the
databases for in vitro and in vivo studies that investigated the effect of zinc on 
 
bone health via regulation of RANKL/RANK/OPG pathway. Additionally, we 
 
tried to find more related studies with manual reference list checking. We used both
MeSH term and free-text in titles/abstracts as follow: ("Zinc"[Mesh] OR “Zinc
supplement*”) AND (“"Bone and Bones"[Mesh]) AND ("RANK 
Ligand"[Mesh] OR “RANKL” OR “RANK” OR “Osteoprotegrin” OR “OPG”. We 
 
did not restrict the searches according to their languages or the type of study. The 




























































using any form of zinc as single or multi-component supplement, 2) studies in 
 
which they investigated the role of zinc in RANKL/RANK/OPG modulation 
 
regarding the bone cells. We primarily searched and identified the eligible in-vivo 
 
and in-vitro studies by electronic searching and manual searching of reference lists 
 
of eligible studies. By secondary screening, ineligible articles were excluded due to 
 
duplication in investigated databases, and being irrelevant to the purpose of the 
 
current review. Subsequently, the details of the pathway and the impact of zinc 
 











There are multiple trace minerals which participate in bone metabolism, such as 
copper, magnesium, fluoride, and zinc [27]. Low level of copper and magnesium in 
serum can lead to depletion in BMD [28, 29]. Zinc is one of the most essential trace 
elements for the body [30], is an important cofactor for DNA and RNA synthesize 
enzymes, and is a major stimulant for growth [31], and could interfere in chemical 
catalysis or indirectly participate in protection of protein structure [32]. Zinc food 
sources include; red meat, poultry, shellfish, seeds, nuts, dairy, and beans [33], and 
a reported 2 billion people suffer from zinc deficiency, necessitating 




























































effects and different absorption rates based on their composition, with zinc sulfate, 
zinc picolinate, zinc acetate, zinc gluconate, zinc orotate, and zinc citrate are 
available zin supplements in market [35-37]. Zinc deficiency can result in, for 
example, alopecia, dermatitis, loss of appetite, immune system dysfunction, and 
growth retardation [38, 39]. Conversely, zinc toxicity includes issues such as nausea, 
vomiting, lethargy, fatigue and epigastric pain [40]. There is about 2-3 gr zinc in the 
human body and approximately 0.1% of this amount is excreted which and thus must 
be replenished through dietary intake [31]. A great amount of total body zinc esides 
in the skeleton [41]. It has been shown that zinc has an essential role in bone 
metabolism and mineralization, for instance, in osteoblasts, zinc could activate 
aminoacyl-tRNA synthetase and also prohibit osteoclasts from bone resorption. Zinc 
increases protein synthetase which helps in the protection of bone health [42]. It has 
been suggested that urinary zinc level may be employed as a convenient marker for 
bone loss recognition [43]. Zinc could result in significant upregulation in alkaline 
phosphatase activity which is important for bone calcification and plays an important 
role as a biochemical marker for bone development [44, 45], zinc finger transcription 
factors, TRAF6-inhibitory zinc finger protein and Schnurri-3 [46]. Aging, bone 
unloading and post-menopause may facilitate a reduction in bone zinc quantities 
[25]. Since almost 800 microgram per gram of creatinine is expelled in urine in 




























































zinc is utilized as a marker for bone resorption in postmenopausal women [47]. It 
has been shown that zinc receptors are necessary for the normal matrix and cells in 
bone. Antecedent work has indicated that zinc and its receptor could change the 
expression of some enzymes and adjust collagen production in the skeleton [48]. 
Furthermore, zinc activity in the bone could affect both proliferation and 
differentiation of osteoblast-like cells [49]. Oral intake of zinc supplements could 
help to protect bone from resorption in various conditions, such as aluminum 
toxicity, Ca deficiency, vitamin D deficiency, estrogen deficiency, diabetes, and 
arthritis. So, administration of zinc compounds could add to bone loss protection and 
prevention protocols [50]. Zinc deficiency contributes to many types of 
abnormalities in bones in fetal and postnatal terms [50]. In young animals, where 
zinc deficiency is identified, they face to reduction in somatomedin (IGF-I) synthesis 
and growth problem [51, 52]. A zinc finger transcription factor, Osterix (Osx), is 
expressed in, almost, all growing bones; the genetical role of Osx in bone formation 
and bone homeostasis is well known and operates gene collection for differentiation 
of pre-osteoblasts to osteoblasts and osteocytes [53]. Zinc chelated with β-alanyl-L-
histidine results in the formation of β-Alanyl-L-histidine zinc (AHZ), which can 
stimulate bone formation more than zinc sulfate. In addition, zinc acexamate is 
another compound which has identical effects to AHZ in bone formation, and is 




























































indicate zinc may elicit positive influences on the healing of bone fractures [54, 55]. 
The ability of zinc to suppress osteoclastogenesis is likely because of its inhibitory 
effects on RANKL. Moreover, it may conceivably prevent the pre-osteoclast 








Nf-kB is a superfamily, where constituent proteins take part in the signaling 
pathways [56]. Some of the Nf-kB family members are controlled in inflammatory 
and neoplastic conditions that might be motivated by proinflammatory factors [57]. 
Also, elimination of some of these agents may leads to unwanted bone development 
[58]. One of the most important systems of this family is RANKL/RANK/OPG 
signaling pathway, is regarded an important system for immunity and is essential for 
bone homeostasis [59]. RANK or receptor activator of NF-kB is a transmembrane 
protein contain 3 subunits. It originally discovered in mature osteoblasts, dendric 
cells and osteoclast precursors (OCP) [60]. A deletion mutation in RANK which 
reported in transgenic mice identified the significance of RANK in 
osteoclastogenesis [61]. RANKL (receptor activator of NF-kB ligand also known as 
osteoclast differentiation factor) is a homotrimeric protein, part of TNF superfamily, 




























































expressed by activated T cells, osteoblasts, fibroblasts and stromal cells [62], and 
expressed in mammary gland epithelial cells during pregnancy, causing hyperplasia 
during lactation [63]; in addition, it is expressed in some tumor cells and may control 
their proliferation [64]. Overexpression of RANKL has been observed in various 
diseases such as arthritis rheumatoid and psoriatic arthritis [65, 66]. RANKL is 
regulatable by different agents such as glucocorticoids, TNF-a, TGF-b, IL-1 LSP. 
this protein has the facility to bind to both RANK and OPG 
[59]. OPG (the soluble decoy receptor osteoprotegerin) encoded by TNF receptor 
family member 11B gene (TNFRSF11B) [67], and has been detected during an 
investigation designed for TNFR (tumor necrosis factor receptor) related molecules 
[68]. OPG mRNA has been found in many cell types, including skin, liver, heart, 
lung and bone marrow stromal cells [69, 70]. The main responsibility of OPG is 
inhibition of RANK matching with RANKL [67]; moreover, OPG could bind to 
TRAIL (TNF-related apoptosis-inducing ligand) to prevent TRAIL-induced 
apoptosis [71]. In addition to RANKL and TRAIL, OPG could bind to some other 
agents like glycosaminoglycans (GAGs), von Willebrand Factor, Factor VIII-von 
Willebrand Factor complex, and syndecan-1 [72]. The RANKL/RANK/OPG system 
has important roles in various organs and conditions such as bone modeling and 
remodeling [61], cancer cells [73], pregnancy [63] , immune system [74], and 











































































Osteoclasts are regarded the most important cells in bone resorption, where 
osteoclast precursors have the potential to maturate via stimulation of some factors. 
Among these factors, there are 2 cytokines; M-CSF, a cytokine that secreted by 
several types of cells like stromal cells and osteoblast, and receptor activator of NF-
kB, part of RANKL/RANK/OPG system [76]. RANKL/RANK/OPG system is 
active in various conditions including vascular calcification [77], cancer [78], bone 
modeling a remodeling, and some genetic disorders [79]. The discovery of 
RANKL/RANK/OPG system in bone turnover in the late 1990s is regarded as an 
important finding for developing bone health [80]. 
The interaction between RANK and its ligand (RANKL), on the external layer of 
OPCs (osteoclast precursor cells), results in maturation of these cells and turning to 
osteoclasts. Osteoclasts which migrated to the bone surface, secretion of some 
enzyme like cathepsin K and tartrate-resistant acid phosphatase, and acceleration of 
bone resorption. Osteoprotegerin expressed by bone stromal cells and osteoblasts, 




























































RANK and RANKL with its higher affinity to RANKL [81]. The OPG-RANKL 
ratio is less than 1 in postmenopausal women [49], with some studies reported that 
blocking RANKL leads to an increase in OPG level, and could noticeably reduce 
bone loss during lactation [82]. The timing of RANK expression and its link to 
RANKL is a serious issue in osteoclastogenesis [83]. Both RANKL and RANK must 
be present in order for osteoclastogenesis to happen, where, in mice unable to 
express RANK and RANKL, they suffered from osteopetrosis [84]. However, in 
mice with OPG deficiency, osteoporosis occurred earlier than normal mice, 
attributed to the high number of osteoclasts differentiation [85]. OPG overexpression 
in animal models has resulted in deep osteoporosis to the extent that a total loss in 
osteoblasts happen [86]. Rheumatoid arthritis is an inflammatory disease that can 
weaken bone in numerous ways. RANKL is one of the factors that have expected to 
take part in RA bone problems. Suppressing RANKL and other agents like TNF 
represent a promising treatment for minimizing RA Complications 
[87]. Paget disease is another bone disorder with the Interference of RANKL-
RANK in its development [88]. Paget disease of bone is mainly identified by central 
bone resorption and increased osteoclast activity. In PDB, RANKL expression and 
its sensitivity increases which leads to more bone problems [89]. Recent studies 
regarding bone cancer have investigated signaling systems in this disease; RANKL 




























































tumors while OPG could be decreasing cancer-induced bone pain [73, 90]. Tumor 
cells upregulating RANKL expression in bone stromal cells through increasing IL-
6, IL-1B, TNF, epidermal growth factor and PTH-related peptide (PTH-rP), so 
osteoclastogenesis increased [91]. In this case, using the anti-RANKL treatment 
such as anti-RANKL medication (like denosumab) or gene therapy might have 
significant effects in cancer development [92]. Furthermore, recent investigations 
has suggested that mechanical pressure could lead osteocytes to recall osteoclasts to 















The aim of this study was to review the effect of zinc on RANKL/RANK/OPG 
pathway in the skeleton. In a recent animal study, zinc supplementation in 
ovariectomized (OVX) and diabetic (T1DM) rats resulted in increases in OPG 
expression that led to marked decreases in RANKL/OPG ratio [93]. Another study 
indicated zinc antioxidant property might prevent RANKL/RANK/OPG disbalance 
in Cd-induced rats [94], whilst an in vitro study on mouse marrow cells indicated 




























































[95]. Additionally, zinc sulfate could increase OPG mRNA expression after 24-48 
hours in cultured cells, based on an in-vitro study [96]. The reports of a study 
regarding the effects of zinc demonstrated that as a result of using a zinc-free diet, 
the expression of RANK reduced and the level of RANKL and OPG did not change. 
Overall, [97] indicated that zinc deficiency could decrease both osteoclastogenesis 
and osteoblastogenesis [97]. The result of an in vitro investigation regarding M-CSF 
and RANKL highlighted that zinc can prevent osteoclasts differentiation by the 
dose-depending reduction in RANKL [98]. In a recent study, the effects of Puerarin 
and zinc on ovariectomized rat (OVX) bones demonstrated co-supplementation 
decreased RANKL and increased OPG and OPN (osteopontin) [99]. It was further 
demonstrated that RANKL worked through indirect Ca2+ signaling mediation 
[100]. Based on a rat study, adequate consumption of zinc likely does not affect 
osteoblastogenesis, but it may reduce osteoclastogenesis via suppression of RANK 
expression through prevention of ROS (reactive oxygen species) production and 
ERK (extracellular signal-regulated kinase) activation [101]. A recent study has 
shown, in the group of mice in the TNF inflammatory environment, with a higher 
concentration on Zn, RANKL expression is meaningfully diminished [102]. The 
effect of zinc supplementation on diabetic induced bone loss has been investigated 
through an animal study, demonstrating that supplementation can reduce chronic 




























































by increasing OC (osteocalcin) and decreasing RANKL and OPG [103]. Also, 
another experiment on diabetic rat demonstrated a reduction in RANK expression 
via zinc supplementation [104]. In Fong et. al, a higher ratio of RANKL/OPG was 
reported in a metallothionein knockout (MT -/-) group and received a lower amount 
of zinc compared to others [105]; whilst, according to Liang et. al, zinc could affect 
OPG gene expression in osteoblasts and increasing it [106]. 
In contrast to these studies, there are some studies which show distinct 
consequences. In a study on male rats that received zinc supplements, it was reported 
that dietary zinc supplementation upregulated RANKL expression in bone by TNF-
α and IL-1β; this resulted in bone loss without any specific change in the size of 
bones [107]. It was shown in another animal study that suppressing ZIP4 (Zinc 
transporter ZIP4) could up-regulate bone mineral density and down-regulate bone 
turnover in mice with pancreatic cancer via RANKL-RANK system [108]; whilst 
some work has reported that zinc-modified titanium (EZ) affects osteoblasts 






In conclusion, it is likely that sufficient zinc intake will elicit positive effects on bone




























































studies are equivocal, it seems that zinc can exert the protective properties against 
 
bone loss by suppressing osteoclastogenesis via downregulation of 
 
RANKL/RANK. Additionally, there are several experiments where zinc 
 
supplementation resulted in upregulation of OPG expression. However, the results 
 
of limited studies oppose this. Therefore, aside from the positive role zinc 
 
possesses in preserving bone mass, further effects of zinc in RANKL/RANK/OPG 
 
system requires further animal/human studies. 
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Figure 1: Binding between RANKL and RANK lead to maturation in osteoclasts and enhance bone resorption. OPG, as RANKL decoy receptor, 
would prevent of RANKL/RANK binding and down-regulating bone loss. Most of the studies have reviewed, indicated a significant reduction in 
RANKL and increment in OPG. RANKL (receptor activator of NF-kB ligand), RANK (receptor activator of NF-kB), OPG (osteoprotegerin). 
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Table 1: Summary of the reviewed studies, describing the effects of Zn on RANKL/RANK/OPG pathway in skeleton. RANK 
(receptor activator of Nf-kB), RANKL (receptor activator of NF-kB ligand), OPG (osteoprotegerin) and OVX 
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